Informal CVD Caregiving Costs Estimated at $61 Billion in 2015

Share this content:
Informal CVD Caregiving Costs Estimated at $61 Billion in 2015
Informal CVD Caregiving Costs Estimated at $61 Billion in 2015

MONDAY, April 9, 2018 (HealthDay News) -- The costs of informal caregiving for patients with cardiovascular disease (CVD) were estimated at $61 billion in 2015 and are set to more than double by 2035, according to a policy statement published online April 9 in Circulation.

Sandra B. Dunbar, R.N., Ph.D., from Emory University in Atlanta, and colleagues used data from the 2014 Health and Retirement Survey to estimate hours of informal caregiving for individuals with CVD by age, sex, and race. Data were analyzed for 16,731 non-institutionalized adults aged ≥54 years.

The researchers estimated the costs of informal caregiving to be $61 billion in 2015 for patients with CVD, and these were projected to increase to $128 billion in 2035. More than half the total costs of informal caregiving for patients with CVD were attributable to the costs of informal caregiving for stroke patients ($31 billion in 2015 and $66 billion in 2035). In 2015 costs were highest for those aged 65 to 79 years, but by 2035 these are expected to be surpassed by costs for those aged ≥80 years. For patients with CVD, costs of informal caregiving represent an additional 11 percent of medical and productivity costs.

"These estimates have important research and policy implications, and they may be used to guide policy development to reduce the burden of CVD on patients and their caregivers," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Cap'n Crunch Cereal Recalled Due to Salmonella Scare

Cap'n Crunch Cereal Recalled Due to <i>Salmonella</i> Scare

No illnesses related to the products have been reported to date

FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma

FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma

Adcetris approved in combination with chemo to treat systemic anaplastic large cell lymphoma

FDA Warns Against Giving Honey-Filled Pacifiers to Infants

FDA Warns Against Giving Honey-Filled Pacifiers to Infants

Four infants in Texas hospitalized with botulism after using pacifiers containing honey

is free, fast, and customized just for you!




Already a member?

Sign In Now »